ReviewCurrent opinion in genetics & development2018
Advances in functional genetic screening with transposons and CRISPR/Cas9 to illuminate cancer biology.
Review in Current opinion in genetics & development, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Targeted genome-modification tools and their advanced applications in crop breeding.Nature reviews. Genetics · 2024Review
- High-Throughput Identification, Modeling, and Analysis of Cancer Driver Genes In Vivo.Cold Spring Harbor perspectives in medicine · 2023Review
- Overexpression of lncRNAs with endogenous lengths and functions using a lncRNA delivery system based on transposon.Journal of nanobiotechnology · 2021Article
- Article
- New insights on CRISPR/Cas9-based therapy for breast Cancer.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2021Review
- Review
- Forward and Reverse Genetics of B Cell Malignancies: From Insertional Mutagenesis to CRISPR-Cas.Frontiers in immunology · 2021Review
- A Genetic Screen to Identify Gain- and Loss-of-Function Modifications that Enhance T-cell Infiltration into Tumors.Cancer immunology research · 2020Article
- CRISPR and transposon in vivo screens for cancer drivers and therapeutic targets.Genome biology · 2020Review
- Decoding pluripotency: Genetic screens to interrogate the acquisition, maintenance, and exit of pluripotency.Wiley interdisciplinary reviews. Systems biology and medicine · 2020Review
- Src-Dependent DBL Family Members Drive Resistance to Vemurafenib in Human Melanoma.Cancer research · 2019Article
- A simplified transposon mutagenesis method to perform phenotypic forward genetic screens in cultured cells.BMC genomics · 2019Article
- Importance of genetic screens in precision oncology.ESMO open · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Large-scale genome sequencing studies have identified a wealth of mutations in human tumors and have dramatically advanced the field of cancer genetics. However, the functional consequences of an altered gene in tumor progression cannot always be inferred from mutation status alone. This underscores the critical need for complementary methods to assign functional significance to mutated genes in cancer. Transposons are mobile genetic elements that serve as powerful tools for insertional mutagenesis. Over the last decade, investigators have employed mouse models with on-demand transposon-mediated mutagenesis to perform unbiased genetic screens to identify clinically relevant genes that participate in the pathogenesis of human cancer. Two distinct DNA transposon mutagenesis systems, Sleeping Beauty (SB) and PiggyBac (PB), have been applied extensively in vivo and more recently, in ex vivo settings. These studies have informed our understanding of the genes and pathways that drive cancer initiation, progression, and metastasis. This review highlights the latest progress on cancer gene identification for specific cancer subtypes, as well as new technological advances and incorporation of the CRISPR/Cas9 toolbox into transposon-mediated functional genetic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.